Read by QxMD icon Read

Journal of Cardiovascular Pharmacology

Lu Zhang, Qi Liu, Hui Zhang, Xue-Dong Wang, Shu-Yuan Chen, Yang Yang, Hang Lv, Jing-Bo Hou, Bo Yu
During the pathogenesis of early atherosclerosis, lipid-loaded macrophages are involved in plaque development and progression. As a novel adipokine, C1q/tumor necrosis factor-related protein-9 (CTRP9) has beneficial effects in cardiovascular disease. However, previous reports have not studied whether the formation of macrophage foam cell induced by ox-LDL is affected by CTRP9. According to our study, in ox-LDL-induced THP-1 macrophages, CTRP9 could reduce the quantity of lipid droplets, lower the level of cholesteryl ester (CE), promote cholesterol efflux as well as increase the expression level of the cholesterol transport receptors ATP-binding membrane cassette transporter A1 (ABCA1) and G1 (ABCG1)...
July 3, 2018: Journal of Cardiovascular Pharmacology
Zhen Wang, Ken Chen, Yu Han, Hua Zhu, Xinyu Zhou, Tao Tan, Jing Zeng, Jun Zhang, Yukai Liu, Yu Li, Yonggang Yao, Jianxun Yi, Duofen He, Jingsong Zhou, Jianjie Ma, Chunyu Zeng
Irisin, a muscle-origin protein derived from the extracellular domain of the fibronectin domain-containing 5 protein (FNDC5), has been shown to modulate mitochondria welfare through paracrine action. Here we test the hypothesis that irisin contributes to cardioprotection after myocardial infarction by preserving mitochondrial function in cardiomyocytes. Animal model studies show that intravenous administration of exogenous irisin produces dose-dependent protection against ischemia/reperfusion (I/R)-induced injury to the heart as reflected by the improvement of left-ventricular ejection fraction and the reduction in serum level of cTnI (n=15, P<0...
July 3, 2018: Journal of Cardiovascular Pharmacology
Dimitrios Dimitroulis, Milad Golabkesh, David Naguib, Betül Knoop, Lisa Dannenberg, Carolin Helten, Martin Pöhl, Christian Jung, Malte Kelm, Tobias Zeus, Amin Polzin
Prasugrel and ticagrelor are recommended over clopidogrel in patients with ST-elevation myocardial infarction (STEMI). In this registry analysis, we compared efficacy and safety of ticagrelor and prasugrel P2Y12 inhibition in STEMI patients. We included 318 patients in this single-center analysis. 12 months follow-up was conducted during ambulatory care at our department. Patients were on dual antiplatelet therapy with aspirin and ticagrelor or prasugrel during the follow-up period. Prescription of prasugrel or ticagrelor respectively was according to the preference of the treating physician...
June 27, 2018: Journal of Cardiovascular Pharmacology
Stephen Y Wang, Terrence D Welch, Rajbir S Sangha, Robert W Maloney Pharm D, Zhu Cui, Aaron V Kaplan
Dofetilide is an antiarrhythmic drug with dosing based on the Cockcroft-Gault formula using total body weight (TBW). We investigated the impact of calculating dofetilide dose using adjusted body weight (ABW) or ideal body weight (IBW) on subsequent dose reduction or discontinuation. We conducted a retrospective review of 265 patients admitted to an academic medical center for initiation of dofetilide using TBW. Dosing was recalculated using ABW or IBW. Patients who would have received a reduced dose using ABW or IBW (Reduced Dose Group) were compared to patients whose dose would not have changed (Same Dose Group)...
June 27, 2018: Journal of Cardiovascular Pharmacology
Agnieszka Janion-Sadowska, Elżbieta Papuga-Szela, Robert Łukaszuk, Magdalena Chrapek, Anetta Undas
AIMS: Thrombocytopenia was one of the exclusion criteria in randomized trials in which non-vitamin K antagonist oral anticoagulants (NOACs) were tested. The safety of NOACs in patients with atrial fibrillation (AF) and thrombocytopenia remains unclear. METHODS: We studied 62 AF patients aged from 53 to 85 (mean 70.5) years with platelet count from 50 to 100×109/L who were treated with rivaroxaban 15 mg once daily (33.9%), dabigatran 110 mg bid (54.8%) or apixaban 2...
June 27, 2018: Journal of Cardiovascular Pharmacology
Li Zhou, Xiang Liu, Zhen-Qing Wang, Yan Li, Mao-Mao Shi, Zhe Xu, Zhi-Jun Ou, Hua-Ming Li, Tian-Pu Cheng, Yu-Peng Jian, Wen Zhang, Chen Liu, Xi Zhang, Michael J Quon, Chun-Xiang Zhang, Ying-Qi Xu, Zhi-Ping Wang, Jing-Song Ou
Simvastatin treatment is cardioprotective in patients undergoing non-coronary artery cardiac surgery. However, the mechanisms by which simvastatin treatment protects the myocardium under these conditions are not fully understood. Seventy patients undergoing noncoronary cardiac surgery, 35 from a simvastatin treatment group and 35 from a control treatment group, were enrolled in our clinical study. Simvastatin (20 mg/d) was administered pre-operatively for 5-7 days. Myocardial tissue biopsies were taken before and after surgery...
June 27, 2018: Journal of Cardiovascular Pharmacology
Rinat A Mukhamadiyarov, Evgeniya A Senokosova, Sergey S Krutitsky, Darya V Voevoda, Inna A Pyshnaya, Vladimir V Ivanov, Martin J Lewis, Igor Khaliulin
Liposomes have the potential to be used for drug delivery. Meanwhile, liposome size may affect their accumulation in the target tissue. We investigated the myocardial accumulation of two populations of liposomes (∼70 and 110 nm diameter) during ischaemia and their effect on ischaemia/reperfusion injury.Isolated rat hearts were subjected to 30 min low-flow ischemia with the liposomes followed by 30 min liposome-free reperfusion. The liposomes were loaded with the fluorescent dye Nile Red to assess their accumulation in myocardium...
May 28, 2018: Journal of Cardiovascular Pharmacology
Paul M L Janssen, Benjamin D Canan, Ahmet Kilic, Bryan A Whitson, Anthony J Baker
Recent studies report that a single subtype of α1-adrenergic receptor (α1-AR), the α1A-subtype, mediates robust cardioprotective effects in multiple experimental models of heart failure, suggesting that the α1A-subype is a potential therapeutic target for an agonist to treat heart failure. Moreover, we recently found that the α1A-subtype is present in human heart. The goal of this study was to assess the inotropic response mediated by the α1A-subtype in human myocardium, and to determine if the response is down-regulated in myocardium from failing human heart...
May 25, 2018: Journal of Cardiovascular Pharmacology
Fernando G Stocco, Ederson Evaristo, Anderson C Silva, Victor Zandona de Antonio, Juergen Pfeiffer, Narasimhan Rangachari, Luiz Belardinelli, Richard L Verrier
We compared the pharmacokinetic (PK) profile and electrocardiographic (ECG) changes in response to intratracheal instillation of flecainide acetate into the left atrium and ventricle with intravenous (IV) flecainide acetate administration. In 12 closed-chest anesthetized Yorkshire pigs, we monitored QRS complex and PR, JTc, and QTc intervals during sinus rhythm and correlated changes with venous plasma drug concentrations before and at 2, 5, 10, 15, and 30 min after drug administration. Intratracheal instillation of flecainide (0...
May 25, 2018: Journal of Cardiovascular Pharmacology
Lida Feyz, Soma Bahmany, Joost Daemen, Anton H van den Meiracker, Birgit C P Koch, Teun van Gelder, Jorie Versmissen
Resistant hypertension (RH) is a common health problem leading to suboptimal cardiovascular prevention. A large number of patients with RH have poor medication adherence explaining their assumed resistance to therapy. We combined directly observed therapy (DOT) with therapeutic drug monitoring (TDM) in three patients at several time points to enable an extensive feedback on blood pressure (BP) and drug levels. BP was measured with an automatic oscillatory device at regular intervals of 5 minutes (directly before and after drug intake) and at 30 minute intervals (at night) during admission...
May 23, 2018: Journal of Cardiovascular Pharmacology
Lourdes Vicent, Alberto Esteban-Fernández, Manuel Gómez-Bueno, Javier De-Juan, Pablo Díez-Villanueva, Ángel Manuel Iniesta, Ana Ayesta, Hugo González-Saldívar, Antonio Rojas-González, Ramón Bover-Freire, Diego Iglesias, Marcos García-Aguado, Jesús A Perea-Egido, Manuel Martínez-Sellés
Our aim is to describe the characteristics of the patients receiving sacubitril/valsartan (SV) in daily clinical practice. This is a prospective registry in 10 hospitals including all patients who started SV in everyday clinical practice.From October 2016 to March 2017, 427 patients started treatment with SV. The mean age was 68.1±12.4 years and 30.5% were women (22.0% in PARADIGM-HF, p<0.001). Comparing our cohort with patients included in PARADIGM-HF, baseline treatment was different, with a lower ratio of angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (2...
May 21, 2018: Journal of Cardiovascular Pharmacology
Martin Stroethoff, Iris Christoph, Friederike Behmenburg, Annika Raupach, Sebastian Bunte, Semra Senpolat, André Heinen, Markus W Hollmann, Alexander Mathes, Ragnar Huhn
Activation of melatonin receptors induces cardioprotection. Mitochondrial potassium channels (mKCa and mKATP) are involved in the signalling cascade of preconditioning. The melatonin receptor agonist ramelteon is an approved oral medication for treatment of insomnia but nothing is known about possible cardioprotective properties. We investigated whether (1) ramelteon induces cardioprotection mediated by the melatonin receptor; (2) this effect is concentration-dependent; and (3) mKCa- and/or mKATP-channels are critically involved in ramelteon-induced cardioprotection...
May 21, 2018: Journal of Cardiovascular Pharmacology
Richard L Verrier
No abstract text is available yet for this article.
May 3, 2018: Journal of Cardiovascular Pharmacology
Po-Cheng Chang, Yu-Ying Lu, Hui-Ling Lee, Shien-Fong Lin, Yen Chu, Ming-Shien Wen, Chung-Chuan Chou
Calcium homeostasis plays an important role in development of early afterdepolarizations (EADs) and torsade de pointes (TdP). The role of sodium-calcium exchanger (NCX) inhibition in genesis secondary Ca rise and EADs-TdP is still debated. Dual voltage and intracellular Ca optical mapping were conducted in 6 control and 9 failing rabbit hearts. After baseline electrophysiological and optical mapping studies, E4031 was given to simulate long QT syndrome. ORM-10103 was then administrated to examine the electrophysiological effects on EAD-TdP development...
May 3, 2018: Journal of Cardiovascular Pharmacology
Jia-Lin Wang, Duo Gong, Xin-Yan Hu, Su Wu, Xi-Long Zheng, Jie Wu, Xiao-Er Tang, Da-Wei Zhang, Chao-Ke Tang
OBJECTIVE: The aim of this study was to determine whether the apolipoprotein A-1 (apoA-1) mimetic peptide ELK-2A2K2E regulates inflammatory cytokine expression via activating the ATP-binding cassette transporter A1 (ABCA1)-janus kinase 2 (JAK2)-signal transducer and activator of transcription 3 (STAT3)- tristetraprolin (TTP) signaling pathway in THP-1 macrophage-derived foam cells. METHODS AND RESULTS: The cells were treated with the apoA-1 mimetic peptide ELK-2A2K2E at different concentrations (0, 20, 40, 80 μg/ml) or incubated with ELK-2A2K2E (40 μg/ml) for different times (0, 6, 12, 24 h)...
May 3, 2018: Journal of Cardiovascular Pharmacology
John S Van Taunay, M Teresa Albelda, Juan Carlos Frias, Michael J Lipinski
The advent of biologic therapy has enhanced our ability to augment disease in an increasingly targeted manner. The use of biologics in cardiovascular disease (CVD) has steadily increased over the past several decades. Much of the early data on biologics and CVD were derived from their use in rheumatologic populations. Atherosclerosis, myocardial infarction, and heart failure have been closely linked to the inflammatory response. Accordingly, cytokines such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 have been targeted...
May 3, 2018: Journal of Cardiovascular Pharmacology
Christine Driver, Kayode Dominion Samuel Bamitale, Aniessa Kazi, Mehnaaz Olla, Annah Ntsoaki Nyane, Peter Mark Oroma Owira
Metformin, routinely used as first-line drug in the treatment of type 2 diabetes has been shown to have cardioprotective effects beyond its glycemic control. These have been attributed to increases in Akt concentrations and activation of protein kinases in the RISK pathways. which prevent the mitochondrial mPTP from opening and rupturing it and therefore protects myocyte viability. In myocardial infarction and subsequent reperfusion, metformin activation of AMPK promotes glycolysis and keeps the mPTP closed...
May 3, 2018: Journal of Cardiovascular Pharmacology
Ioannis K Rizos, James N Tsoporis, Ioannis K Toumpoulis, Vasileios Salpeas, Shehla Izhar, Angelos G Rigopoulos, Eleftherios A Sakadakis, Thomas G Parker
Heat shock proteins (HSP) play an important role in the cellular adaptation to stress, a requisite for cell survival. The aortic wall appears to be a target for increased expression of HSP during surgical stress. We aimed to define the expression and function of aortic HSP70 in 31 patients with normal ascending thoracic aortic diameter who underwent aortic valve replacement due to aortic valve stenosis (AVS) and in 35 patients with dilated ascending thoracic aorta who underwent replacement of an ascending thoracic aortic aneurysm (ATAA)...
May 3, 2018: Journal of Cardiovascular Pharmacology
Leo F Buckley, Salvatore Carbone, Cory R Trankle, Justin M Canada, Claudia Oddi Erdle, Jessica A Regan, Michele M Viscusi, Dinesh Kadariya, Hayley Billingsley, Ross Arena, Antonio Abbate, Benjamin W Van Tassell
BACKGROUND: Interleukin-1 (IL-1) blockade appears to improve anaerobic exercise in patients with systolic heart failure through improved left ventricular systolic performance. However, it is unclear whether IL-1 blockade affects left ventricular systolic performance. METHODS: We pooled data from two clinical trials of patients with systolic heart failure who were randomized to IL-1 blockade or placebo. We estimated changes in left ventricular systolic performance (left ventricular ejection fraction [LVEF] and end-systolic elastance [LVEes]) and pressure-volume area, a surrogate of oxygen consumption, after 14 days of treatment...
April 30, 2018: Journal of Cardiovascular Pharmacology
Tomáš Bolek, Matej Samoš, Ingrid Škorňová, Frantisek Kovář, Peter Galajda, Ján Stasko, Peter Kubisz, Marián Mokáň
Proton pump inhibition (PPI) administrated together with antiplatelet and anticoagulant agents reduces the risk of gastrointestinal hemorrhage. Several novel antithrombotic agents have been recently introduced for acute coronary syndrome patients (prasugrel, ticagrelor), or for patients requiring long-term anticoagulation (dabigatran, rivaroxaban, apixaban, edoxaban, betrixaban). In fact, these agents might offer even stronger inhibition of platelets or coagulation compared with older agents; and therefore, the need for gastroprotection might be even stronger when these new agents are used for long-term antithrombotic therapy...
April 24, 2018: Journal of Cardiovascular Pharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"